Accord Healthcare Receives Positive CHMP Opinion For Denosumab, Osvyrti®, And Jubereq®
Denosumab marks Accord's sixth biosimilar approval in Europe. The CHMP has issued a positive opinion for Denosumab, to be marketed as Osvyrti® and Jubereq®. Osvyrti® is Accord's second osteoporosis biosimilar, following Sondelbay®. The CHMP's …